benzoxazoles has been researched along with Adenoma Sebaceum in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajaj, V; Guo, Y; Kwiatkowski, DJ; Malinowska, IA; Mrozek, EM; Zhang, J | 1 |
| Guo, Y; Kwiatkowski, DJ | 1 |
2 other study(ies) available for benzoxazoles and Adenoma Sebaceum
| Article | Year |
|---|---|
Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Topics: Animals; Benzoxazoles; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Naphthyridines; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Xenograft Model Antitumor Assays | 2021 |
Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Topics: Animals; Benzoxazoles; Cell Growth Processes; Cystadenoma; Disease Models, Animal; Immunohistochemistry; Kidney Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Phosphorylation; Pyrimidines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tuberous Sclerosis | 2013 |